TGFB1 and neoplasm: C707 harbors a SMAD4 mutation that renders the tumor cells insensitive to TGF-β signaling pathway disruption, lending credence to the hypothesis that the effect of galunisertib treatment we observe on the tumor is through the tumor-associated stroma.